In AF after TAVR, edoxaban was noninferior to VKAs for a composite of adverse events but increased major bleeding.
Where this comes from
- Record sourced from PubMed, PMID 35099999.
- Also identified by DOI 10.7326/J21-0014.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Van Mieghem NM, Unverdorben M, Hengstenberg C, et al. <b>Edoxaban versus vitamin K antagonist for atrial fibrillation after TAVR.</b> N Engl J Med. 2021;385:2150-60. 34449183.
Medical subject headings
- Atrial Fibrillation
- Transcatheter Aortic Valve Replacement